Amgen Stock Reaches Near 52-Week High as Investors Adjust Positions

Amgen's stock price has reached near its 52-week high of USD 447.03, and major investors are adjusting their positions.

In recent months, institutional investors have been repositioning around Amgen, as evidenced by the latest regulatory filings.

For example, asset manager Amundi reported a position of 512,883 Amgen shares, while HighTower Advisors LLC trimmed its stake by 4,063 shares.

The current market capitalization of Amgen stands at USD 236.38 billion, with a price-to-earnings ratio of 27.17 and a price-to-earnings-growth (PEG) ratio of 3.15 as of early September 2026.

Amgen's earnings growth and guidance underpin its valuation, with the company reporting USD 6.29 per share in its latest reported quarter, beating analysts' consensus estimate by USD 0.67 on revenue of USD 10.05 billion compared to expectations of USD 9.43 billion.